Press Releases

CPHI Korea is a dynamic meeting place where pharmaceutical suppliers, purchasers and decision makers get together for three days of uninterrupted business. Online CPHI Korea is also available for ten days. The event’s high-level conference, which runs throughout the three days, gives you in-depth insight into Korea’s pharma/bio/nutraceutical market, covering its latest trends, challenges, and opportunities. CPHI is dedicated to ingredient manufacturin

At the Euromar 2022 Conference, Bruker announced three new customer orders for GHz systems, which will incorporate novel, compact 1.0 GHz NMR magnets for structural biology applications and clinical research in single-story laboratories. The new Ascend Evo 1.0 GHz NMR magnet, operating at 4.2 Kelvin, allows functional structural biology and clinical phenomics researchers to dive deeper into the structural details, binding and dynamics of molecular structures and complexes for fundamental cell

Thoughtworks , a global technology consultancy that integrates strategy, design and engineering to drive digital innovation, today announced the signing of a multi-year agreement with PCI Pharma Services, a leading global contract development and manufacturing organization (CDMO). Thoughtworks will help PCI in its journey to digitize its supply chain, with the goal of accelerating the time it takes to bring clients’ life-changing therapies to market for patients. By co-develop

AIDS Healthcare Foundation (AHF) today praised the U.S. National Institutes of Health (NIH) for committing to share innovative technologies with a South Africa-based biotech company, Afrigen, which should speed up the development and rollout of modern, highly-effective vaccines in low- and middle-income countries, including on the African continent. “We have entered a new age of pandemics, which demands a new way of fighting infectious diseases. As we have seen so clearly with

invoX Pharma Limited (“invoX”), a wholly owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) commenced a cash tender offer for all of the issued and outstanding shares of common stock of F-star Therapeutics, Inc. (“F-star”) (NASDAQ:FSTX) for a price of $7.12 per share. The tender offer is being made pursuant to an Offer to Purchase, dated July 7, 2022 (the “Offer to Purchase”), and in connection with the previousl

Sirio Pharma Co., Ltd. (Sirio) – the global nutraceutical contract development and manufacturing organization (CDMO) – and Best Formulations, Inc. (Best) today announced that they have entered into an agreement for Sirio to acquire 80% equity of Best, a contract manufacturer of nutraceuticals and dietary supplements based in City of Industry, California. Best Formulations, founded in 1984, is a leading contract manufacturer of softgels in North America. It engages in the

QHP Capital (“QHP”), the management company for NovaQuest Private Equity (“NQPE”), today announced its acquisition of Lexitas Pharma Services (“Lexitas” or the “Company”), a full-service ophthalmology contract research organization (“CRO”) supporting biopharmaceutical and medical device clinical trials. Since 2011, Lexitas has provided clinical trial and medical strategy solutions to biopharmaceutical and medical device com

Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced that it is launching the Inscopix Data Exploration, Analysis and Sharing (IDEAS) Platform to help neuroscience research groups improve how they analyze and organize neuroscience data. Initially launched in December 2021 as an enterprise-friendly solution, the cloud-based IDEAS Platform is the first-of-its-kind turnkey solution for multimodal preclinical research data and a powe

WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new large-scale oligonucleotide and peptide manufacturing facility at its Changzhou campus. The new facility underscores WuXi STA's ongoing commitment to enhance its capacity and capability to meet the fast-growing customer needs for oligonucleotide and peptide therapeutics development and manufacturing worldwide, making more innovative therapies accessible to the patients. With the opening of the new 30,570

Albireo Pharma, Inc.  a rare liver disease company developing novel bile acid modulators, today announced that The Lancet Gastroenterology & Hepatology published the results of the pivotal PEDFIC 1 trial, which evaluated Bylvay® (odevixibat) for the treatment of progressive familial intrahepatic cholestasis (PFIC). The study met both of its two primary endpoints, demonstrating that Bylvay provided statistically significant improvements in pruritus severity scores and reductions i